التفاصيل البيبلوغرافية
| العنوان: |
Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. |
| المؤلفون: |
Sasse, Stephanie, Rothe, Achim, Goergen, Helen, Eichenauer, Dennis A., Lohri, Andreas, Kreher, Stephan, Jäger, Ulrich, Bangard, Christopher, Kuhnert, Georg, Böll, Boris, von Tresckow, Bastian, Engert, Andreas |
| المصدر: |
Leukemia & Lymphoma; Oct2013, Vol. 54 Issue 10, p2144-2148, 5p |
| مصطلحات موضوعية: |
HEALTH outcome assessment, CANCER relapse, DISEASE relapse, STEM cell transplantation, COMPLICATIONS from organ transplantation, HODGKIN'S disease treatment, SALVAGE therapy, PATIENTS |
| مستخلص: |
Only limited data are available on the role of brentuximab vedotin (SGN-35) in transplant-naive relapsed or refractory patients with Hodgkin lymphoma (HL). We thus retrospectively analyzed 14 patients with primary refractory or relapsed HL who were treated with brentuximab vedotin as single agent in a named patient program, who had not received prior high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) due to refractory disease ( n = 9), comorbidity ( n = 4) and unknown reasons ( n = 1). Brentuximab vedotin resulted in an overall response rate of 71% (10/14) with five complete responses (CRs). Five of those patients with refractory disease and four patients with relevant comorbidity responded. Consolidating ASCT ( n = 4) or allogeneic SCT ( n = 1) was performed in five patients. Median progression-free survival (PFS) was 9 months and the median overall survival (OS) was not reached. These data indicate the therapeutic efficacy of brentuximab vedotin in chemotherapy-refractory transplant-naive patients with HL. [ABSTRACT FROM AUTHOR] |
|
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
